The Precision Medicine Company

Developing microbiome-based predictive diagnostic and companion therapeutic products to enable safer and more efficacious drug therapies

UK-wide online survey of people with IBD confirms strong patient support for AlphaBiomics’

predictive diagnostic RxSelex™. Read more here.

The Precision Medicine Company

Developing microbiome-based predictive diagnostic and companion therapeutic products to enable safer and more efficacious drug therapies

Winner of the 2018 European Innovation Quickfire Challenge (read more)